LCTX logo

LCTX
Lineage Cell Therapeutics Inc

7,830
Mkt Cap
$341.25M
Volume
1.17M
52W High
$2.09
52W Low
$0.4477
PE Ratio
-4.92
LCTX Fundamentals
Price
$1.37
Prev Close
$1.37
Open
$1.38
50D MA
$1.59
Beta
1.19
Avg. Volume
1.1M
EPS (Annual)
-$0.2761
P/B
7.48
Rev/Employee
$189,038.96
$329.73
Loading...
Loading...
News
all
press releases
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +4.60% and +8.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
More News
News Placeholder
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Biotechs Racing to...
PR Newswire·29d ago
News Placeholder
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...
PR Newswire·2mo ago
News Placeholder
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -32.74% and -0.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration PR Newswire VANCOUVER...
PR Newswire·3mo ago
News Placeholder
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of -550.00% and +40.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Strength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·7mo ago
News Placeholder
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of +50.00% and +75.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9mo ago
<
1
2
...
>

Latest LCTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.